Company Description
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States.
Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.
The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers.
It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2014 |
| IPO Date | Apr 24, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 100 |
| CEO | Dr. Jacob M. Chacko M.B.A., M.D. |
Contact Details
Address: 240 E. Grand Ave., 2nd Floor South San Francisco, California 94080 United States | |
| Phone | (650) 388-5600 |
| Website | oricpharma.com |
Stock Details
| Ticker Symbol | ORIC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001796280 |
| CUSIP Number | 68622P109 |
| ISIN Number | US68622P1093 |
| Employer ID | 47-1787157 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Richard A. Heyman Ph.D. | Co-Founder, Independent Chairman and Member of Scientific Advisory Board |
| Dr. Jacob M. Chacko M.B.A., M.D. | President, Chief Executive Officer and Director |
| Dominic G. Piscitelli CPA, M.B.A. | Chief Financial Officer |
| Dr. Pratik S. Multani M.D., M.S. | Chief Medical Officer |
| Dr. Charles L. Sawyers B.A., M.D., Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Dr. Scott W. Lowe Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Dr. Lori Sickels Friedman Ph.D. | Chief Scientific Officer |
| Dr. Christian V. Kuhlen Esq., J.D., M.D. | General Counsel |
| Daniel Iazzetti | Vice President and Head of People |
| Dr. Edna Chow Maneval | Senior Vice President of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 24, 2024 | ARS | Filing |
| Apr 24, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 24, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 29, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 29, 2024 | 8-K | Current Report |
| Mar 11, 2024 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Mar 11, 2024 | 10-K | Annual Report |
| Mar 11, 2024 | 8-K | Current Report |
| Mar 11, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Mar 6, 2024 | 144 | Filing |